Table of Contents Show
Precision oncology is no longer a privilege reserved for patients in advanced healthcare economies. Bengaluru based startup 4baseCare is working to change that — and its latest funding round signals that institutional investors are firmly behind the vision.
The company has closed a total of Rs 128 crore in Series B funding. The round comprises two tranches: an initial Rs 90 crore first close led by noted investor Ashish Kacholia alongside Lashit Sanghvi and Yali Capital, followed by a fresh Rs 38 crore top-up led by Infosys and growX Ventures, with continued participation from existing backers. The involvement of Infosys is particularly noteworthy, lending both financial credibility and potential enterprise distribution muscle to 4baseCare’s growth ambitions.
Building the Infrastructure for Genomic Cancer Care
Founded in 2019 by Hitesh Goswami and Kshitij Rishi, 4baseCare operates at the intersection of genomics, artificial intelligence, and clinical oncology. Its flagship platform, OncoTwin, synthesises clinico-genomic and real-world patient data to generate actionable treatment insights for oncologists. Rather than relying solely on generalised treatment protocols, OncoTwin enables physicians to make more informed, data driven decisions tailored to individual patient profiles.
The company currently operates genomics laboratories in India, Dubai, Nepal, and the Philippines, conducting approximately 1,500 tests per month. It has also established an in-hospital lab model through partnerships with institutions such as AIIMS Jammu, Max Healthcare, and Shankara Hospital — a strategy that embeds its capabilities directly within existing clinical workflows.
Scaling Across Underserved Markets
The fresh capital will fund an ambitious international expansion. 4baseCare plans to enter 8–10 new countries over the next 12 to 18 months, with a focus on regions that remain significantly underrepresented in global cancer genomics research — including the Middle East, Southeast Asia, and Latin America. Alongside geographic expansion, the company targets a substantial increase in testing volume, from 1,500 to 8,000–10,000 genomic tests per month.
A Sector Gaining Momentum
4baseCare’s raise reflects a broader surge in investor confidence in India’s oncology technology landscape. Recent funding activity from Everhope Oncology, MOC Cancer Care, ErlySign, OnCare, and OneCell Diagnostics points to a growing recognition that cancer diagnostics and care delivery are ripe for technology driven disruption, particularly in markets where access has historically been limited.
